UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia

G. Almeida, A; Almeida, A; Melo, T; Guerra, L; Lopes, L; Ribeiro, P; Duarte, M; ... Fontes‐Carvalho, R; + view all (2019) New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Revista Portuguesa de Cardiologia , 38 (1) pp. 1-9. 10.1016/j.repc.2017.10.013. Green open access

[thumbnail of Elliott_New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia_VoR.pdf]
Preview
Text
Elliott_New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia_VoR.pdf - Published Version

Download (1MB) | Preview

Abstract

The use of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia has significantly altered the prognosis of this disease, enabling close to normal life expectancy. Despite their undeniable benefits, the use of TKIs is associated with an increased risk of side effects on the cardiovascular system, particularly of atherothrombotic events. It is therefore necessary to understand and prevent the adverse effects of these drugs, in order to enable antileukemic therapy to continue and to minimize patients’ toxic exposure. This multidisciplinary consensus document, developed through a collaboration between hematologists and cardiologists, aims to review the cardiovascular toxicity associated with various TKIs and to establish recommendations for the follow‐up of these patients. Measures are also proposed for the assessment and reduction of cardiovascular risk in these patients and referral criteria, and relevant drug interactions are discussed.

Type: Article
Title: New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.repc.2017.10.013
Publisher version: https://doi.org/10.1016/j.repc.2017.10.013
Language: Portuguese
Additional information: © 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This in an Open Access article published in terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Cardio‐oncology, Chemotherapy, Tyrosine kinase inhibitors, Cardiotoxicity, Chronic myeloid leukemia
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
URI: https://discovery.ucl.ac.uk/id/eprint/10068417
Downloads since deposit
58Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item